|Bid||1.2000 x 800|
|Ask||1.2100 x 900|
|Day's Range||1.2000 - 1.2900|
|52 Week Range||1.0300 - 6.9800|
|Beta (3Y Monthly)||2.97|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.06|
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of December. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
TransEnterix (TRXC) delivered earnings and revenue surprises of 0.00% and -51.53%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Morrisville, North Carolina-based company said it had a loss of 10 cents. Losses, adjusted for amortization costs and non-recurring costs, came to 9 cents per share. The maker ...
TransEnterix, Inc. , a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the first quarter of 2019.
TransEnterix, Inc. announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the 2019 RBC Capital Markets Global Healthcare Conference at The InterContinental New York Barclay in New York City.
TransEnterix (TRXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TransEnterix, Inc. announced today that it plans to release first quarter financial and operating results after the market closes on Thursday, May 9, 2019. Todd M.
Todd Pope became the CEO of TransEnterix, Inc. (NYSEMKT:TRXC) in 2013. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. After that, we will cons...
TransEnterix, Inc. , a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery , today announced it will host several events highlighting digital laparoscopy with the Senhance™ Surgical System–the first new abdominal robotic surgery platform to receive FDA clearance since 2000–at the 2019 Annual Meeting of the Society of American Gastrointestinal ...
NEW YORK , March 19, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. For example, we sympathize with anyone who was caught holding TransEnterix, Inc. (NYSEMKT:TRXC) duringRead More...
TransEnterix, Inc. , a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the fourth quarter and full year 2018.
TransEnterix, Inc. announced today that it plans to release fourth quarter and fiscal year 2018 financial and operating results before the market opens on Tuesday, February 26, 2019.
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced the Company received FDA 510(k) clearance for its Senhance™ Ultrasonic System. “Advanced energy devices are used within a high percentage of cases across a wide range of procedures, which make them a critical tool for laparoscopic surgeons,” said Todd M. Pope, TransEnterix president and CEO.